Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.19)
# 3,576
Out of 4,884 analysts
76
Total ratings
37.97%
Success rate
-20.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Overweight | n/a | $5.86 | - | 11 | Jun 26, 2025 | |
| REPL Replimune Group | Initiates: Overweight | n/a | $9.40 | - | 1 | Jun 20, 2025 | |
| ASND Ascendis Pharma | Reiterates: Overweight | $200 | $174.18 | +14.82% | 18 | May 12, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $36.40 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.29 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $2.89 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.95 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.46 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $22.10 | - | 2 | Jan 13, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.47 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.30 | +365.12% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.43 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.81 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.95 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $2.17 | +38.25% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $5.66 | +3,786.93% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.12 | +346.43% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.75 | +2,071.43% | 1 | Aug 12, 2022 |
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.86
Upside: -
Replimune Group
Jun 20, 2025
Initiates: Overweight
Price Target: n/a
Current: $9.40
Upside: -
Ascendis Pharma
May 12, 2025
Reiterates: Overweight
Price Target: $200
Current: $174.18
Upside: +14.82%
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $36.40
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.29
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.89
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.95
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.46
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.10
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.47
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.30
Upside: +365.12%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.43
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.81
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.95
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $2.17
Upside: +38.25%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $5.66
Upside: +3,786.93%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.12
Upside: +346.43%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.75
Upside: +2,071.43%